The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
The collaboration combines Takara Bio’s large-scale testing technology with Resistomap’s data-driven AMR intelligence
This combination works to break down rough patches, improve moisture retention, and enhance overall skin texture
Muted movement reflects consolidation phase as investors await earnings triggers
Through the partnership, she plans to share her experience—from consultation through recovery—across her social media platforms
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Highlights Mirvetuximab-based regimen promise
Subscribe To Our Newsletter & Stay Updated
